Table 5.
Subgroup meta-analysis results of solifenacin dose.
| Outcomes | Subgroups | WMD (95% Cl) | P | Test for heterogeneity | Analysis model | Sample size | Number of study | ||
|---|---|---|---|---|---|---|---|---|---|
| I2(%) | P | Combination treatment | Tamsulosin monotherapy | ||||||
| TIPSS | >5 mg | −0.500 (−1.104, 0.103) | 0.104 | 55.10% | 0.029 | R | 875 | 873 | 5 |
| ≤5 mg | −2.209 (−3.601, −0.817) | 0.002 | 94.50% | 0.000 | R | 995 | 1,024 | 12 | |
| SIPSS | >5 mg | −0.147 (−0.519, 0.225) | 0.439 | 70.60% | 0.002 | R | 722 | 710 | 5 |
| ≤5 mg | −0.800 (−1.757, 0.157) | 0.102 | 81.00% | 0.000 | R | 276 | 285 | 2 | |
| VIPSS | >5 mg | −0.059 (−0.523, 0.405) | 0.581 | 0.00% | 0.712 | F | 339 | 327 | 2 |
| ≤5 mg | −0.417 (−0.898, 0.063) | 0.089 | 58.10% | 0.014 | R | 721 | 721 | 6 | |
| QMAX | >5 mg | 0.166 (−0.087, 0.420) | 0.198 | 0.00% | 0.484 | F | 476 | 399 | 3 |
| ≤5 mg | 1.843 (0.097, 3.590) | 0.039 | 94.00% | 0.000 | R | 576 | 582 | 10 | |
| OABSS | >5 mg | −1.134 (−2.196, −0.071) | 0.036 | 0.00% | 0.930 | F | 210 | 213 | 2 |
| ≤5 mg | −1.213 (−2.136, −0.289) | 0.010 | 96.40% | 0.000 | R | 403 | 434 | 5 | |
| QOL | >5 mg | −0.100 (−0.266, 0.066) | 0.237 | 0.00% | 0.934 | F | 383 | 355 | 2 |
| ≤5 mg | −0.464 (−0.955, 0.027) | 0.064 | 95.90% | 0.000 | R | 520 | 550 | 7 | |
| PVR | >5 mg | 3.437 (−1.904, 8.778) | 0.207 | 54.00% | 0.042 | R | 646 | 519 | 4 |
| ≤5 mg | −1.398 (−7.752, 4.957) | 0.666 | 82.80% | 0.000 | R | 411 | 440 | 5 | |
| Urgency episodes per 24 h | >5 mg | 0.234 (0.001, 0.468) | 0.049 | 0.00% | 0.992 | F | 602 | 491 | 3 |
| ≤5 mg | 0.225 (0.107, 0.343) | <0.001 | 3.00% | 0.397 | F | 584 | 592 | 3 | |
| Micturitions per 24 h | >5 mg | −0.206 (−0.512, 0.100) | 0.187 | 0.00% | 0.483 | F | 519 | 447 | 2 |
| ≤5 mg | 0.409 (0.157, 0.661) | 0.001 | 39.70% | 0.156 | F | 487 | 549 | 3 | |
| PSA | ≤5 mg | 0.192 (0.132, 0.253) | <0.001 | 0.00% | 0.596 | F | 667 | 689 | 6 |
WMD, Weighted mean difference; CI, confidence interval; R, random effects model; F, fixed effects model; TIPSS, Total International Prostate Symptom Score; SIPSS, Storage International Prostate Symptom Score; VIPSS, Voiding International Prostate Symptom Score; QOL, Quality of life; QMAX, Maximal urinary flow rate; PVR, Post void residual volume; PSA, Prostate specific antigen; OABSS, Overactive bladder symptom score.
Bold values meant P-value < 0.05.